{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:02:55Z","timestamp":1759564975413},"reference-count":26,"publisher":"Elsevier BV","issue":"10-13","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1016\/j.steroids.2003.07.006","type":"journal-article","created":{"date-parts":[[2003,10,30]],"date-time":"2003-10-30T07:33:35Z","timestamp":1067499215000},"page":"927-929","source":"Crossref","is-referenced-by-count":7,"title":["Use of dydrogesterone as a progestogen for oral contraception"],"prefix":"10.1016","volume":"68","author":[{"given":"Herjan J.T.","family":"Coelingh Bennink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Boerrigter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2003.07.006_BIB1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF03189462","article-title":"Dydrogesterone: Metabolism in man","volume":"5","author":"van Amsterdam","year":"1980","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.steroids.2003.07.006_BIB2","first-page":"724","article-title":"Isopregnenone (Duphaston): a new progestational agent","volume":"19","author":"Backer","year":"1962","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.07.006_BIB3","first-page":"266","article-title":"Progestogens: pharmacological characteristics and clinically relevant differences","volume":"3","author":"Barentsen","year":"1996","journal-title":"Eur. Menopause J."},{"key":"10.1016\/j.steroids.2003.07.006_BIB4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0015-0282(16)56991-X","article-title":"A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston)in women with minimal to mild endometriosis","volume":"62","author":"Overton","year":"1994","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.07.006_BIB5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0015-0282(16)46333-8","article-title":"Dydrogesterone versus vaginal progesterone in the treatment of the endometrial luteal phase deficiency","volume":"37","author":"Balasch","year":"1982","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.07.006_BIB6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/oxfordjournals.humrep.a137087","article-title":"A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer","volume":"5","author":"Kupfermine","year":"1990","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.07.006_BIB7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/oxfordjournals.humrep.a136511","article-title":"The effect of dydrogesterone supplementation in an IVF programme","volume":"2","author":"Belaisch-Allart","year":"1987","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.07.006_BIB8","first-page":"191","article-title":"La Dydrogesterone dans le traitement des grossesses hypohormonales","volume":"107","author":"Radulesco","year":"1970","journal-title":"Marseille Medical"},{"issue":"1S","key":"10.1016\/j.steroids.2003.07.006_BIB9","first-page":"77","article-title":"Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with a progesterone (Dydrogesterone)and human chorionic gonadotrophin (hCG)","volume":"70","author":"El-Zibdeh","year":"1998","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.07.006_BIB10","doi-asserted-by":"crossref","unstructured":"Haspels AA. A double-blind, placebo-controlled, multi-center study of the efficacy of dydrogesterone (Duphaston). In: van Keep PA, Utian WH, editors. The premenstrual syndrome. Lancaster, England: MTP Press Limited; 1981. pp. 81\u201392.","DOI":"10.1007\/978-94-011-6255-5_6"},{"key":"10.1016\/j.steroids.2003.07.006_BIB11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1192\/bjp.153.2.232","article-title":"Premenstrual syndrome. A double-blind cross-over study of treatment with dydrogesterone and placebo","volume":"153","author":"Sampson","year":"1988","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.steroids.2003.07.006_BIB12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/02813438809009313","article-title":"The effect of dydrogesterone on premenstrual symptoms. A double-blind, randomized, placebo-controlled study in general practice","volume":"6","author":"Hoffmann","year":"1988","journal-title":"Scand. J. Prim. Health Care"},{"key":"10.1016\/j.steroids.2003.07.006_BIB13","first-page":"645","article-title":"Die Therapie der juvenilen Dysmenorrh\u00f6 mit 6-Dehydro-Retro-Progesteron","volume":"33","author":"Ohlenroth","year":"1982","journal-title":"Med. Welt"},{"issue":"Part 1","key":"10.1016\/j.steroids.2003.07.006_BIB14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/0029-7844(96)00016-6","article-title":"Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding","volume":"87\/5","author":"Nakamura","year":"1996","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.07.006_BIB15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000291913","article-title":"Factors associated with withdrawal bleeding after administration of oral dydrogesterone or medroxyprogesterone acetate in women with secondary amenorrhoea","volume":"42","author":"Battino","year":"1996","journal-title":"Gynecol. Obstet. Invest."},{"issue":"9","key":"10.1016\/j.steroids.2003.07.006_BIB16","first-page":"768","article-title":"Efficacy of dydrogesterone in the treatment of cycle disturbances in adolescence","volume":"69","author":"Sipowicz","year":"1998","journal-title":"Gin. Pol."},{"key":"10.1016\/j.steroids.2003.07.006_BIB17","first-page":"343","article-title":"Dydrogesterone in the regulation of cycle disturbances in adolescence","volume":"70","author":"Chomczyk","year":"1999","journal-title":"Gin. Pol."},{"issue":"4","key":"10.1016\/j.steroids.2003.07.006_BIB18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002512-199711040-00006","article-title":"Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women","volume":"11","author":"Foster","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.steroids.2003.07.006_BIB19","first-page":"23","article-title":"The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: a review","volume":"2","author":"Crook","year":"1995","journal-title":"Eur. Menopause J."},{"key":"10.1016\/j.steroids.2003.07.006_BIB20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0378-5122(00)00219-X","article-title":"17\u03b2-estradiol (1 mg\/day)continuously combined with dydrogesterone (5, 10 or 20 mg\/day)increases bone mineral density in postmenopausal women","volume":"38","author":"Stevenson","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.steroids.2003.07.006_BIB21","first-page":"477","article-title":"Comparason clinique des nouveaux progestag\u00e8nes","volume":"13","author":"Bernard","year":"1962","journal-title":"Gynecol. Prat."},{"key":"10.1016\/j.steroids.2003.07.006_BIB22","first-page":"38","article-title":"Dydrogesterone therapy: clinical observations and laboratory findings in 61 patients","volume":"22","author":"Ullery","year":"1963","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.07.006_BIB23","first-page":"395","article-title":"Notre exp\u00e9rience with dydrog\u00e9sterone","volume":"5","author":"Netter","year":"1962","journal-title":"C.R. Soc. Fr. Gynecol."},{"key":"10.1016\/j.steroids.2003.07.006_BIB24","unstructured":"Brotherton J. Animal biological assessment. In: Sex hormone pharmacology. London: Academic Press; 1976. pp. 42\u201378."},{"key":"10.1016\/j.steroids.2003.07.006_BIB25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1530\/acta.0.0670551","article-title":"Influence of dydrogesterone (6-dehydroretroprogesterone, Duphaston\u00ae)on ovulation in the rat, rabbit and monkey","volume":"67","author":"Claassen","year":"1971","journal-title":"Acta. Endocrin."},{"key":"10.1016\/j.steroids.2003.07.006_BIB26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/humupd\/8.4.345","article-title":"Residual ovarian activity during oral combined steroid contraception","volume":"8","author":"Van Heusden","year":"2002","journal-title":"Hum. Reprod. Update"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X03001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X03001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T11:16:18Z","timestamp":1585221378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X03001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":26,"journal-issue":{"issue":"10-13","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S0039128X03001259"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2003.07.006","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}